Page 7 - Indian Pharma Companies

Aurobindo Pharma's debt pain recedes after calling off deal with Sandoz

Aurobindo was scheduled to acquire the portfolio with an upfront purchase price of $900 million in cash

The post-COVID-19 world

Policymakers and pharma companies will have to work together to speed up trials of new vaccines and legislate to ensure essential drugs and tests are affordable and available

Lincoln Pharma plans to foray into regulated markets, upgrades facility

The company has upgraded its manufacturing facility at Khatraj near Ahmedabad with Rs 30-crore investment

India scores better than US in regulatory action by USFDA in 2019

From FY15 to FY19, Indian manufacturers received fewer warning letters than Chinese counterparts

Indian drug makers take a hit on quality compliance, R&D investments

The trend is unlikely to reverse in the near term, say experts

Pharma industry considering 'ethics inspectors' to ensure better compliance

Pharma players to meet DoP to discuss suggestions around implementing ethical marketing practices code

Pharma firms plan awareness drive to battle cancer scare in antacid

Indian companies have also been hit in their global business.

Three key reasons why CLSA is bullish on pharma MNCs in India

MNC stocks have outperformed local peers for the first time in over a decade and have also significantly outperformed the Nifty over the last 18 months.

Indian pharmaceutical companies spread business to avoid regulatory ire

Increased USFDA import alerts could be reason for finding alternative sites

FDA observations on Telangana plant a fresh headache for Aurobindo Pharma

The Telangana unit in question is an important one contributing about a fifth to US revenues

USFDA impact: DCGI asks states told to put antacids under scanner

The ranitidine market in India is roughly around Rs 700 crore, with about 180 brands

S&P revises Glenmark outlook to 'negative' on weak operating performance

Glenmark's capex for the first quarter of fiscal 2020 was Rs 190 crore, in line with its guidance

China's new drug law may open door for Indian generic medicines: Report

India has been demanding that China open its pharmaceutical market to Indian drugs as part of the efforts to lower the $57 billion trade deficit

300 fresh pharma unit applications up for approval in Gujarat: FDCA

As per the state FDCA commissioner, the state has benefited from the introduction of GST

Aurobindo Q1 profit up 39.5% at Rs 636 crore on strong revenue growth

Revenue from operations rose 28.1% year-on-year to Rs 5,444.6 crore during the quarter under review

India's new drug nods from US dip in Q1 due to increased scrutiny on firms

India's share of ANDA approvals given by the US Food and Drug Administration (USFDA), too, has fallen from 43 per cent in fourth quarter (Q4) of 2018-19 (FY19) to 33 per cent in Q1FY20

Pharma funds remain in poor health amid headwinds on compliance

The BSE Healthcare Index has fallen 10 per cent in the last one year

What's bugging Indian, Chinese medicine companies making crucial heart drug

US inspectors cite Cadila Healthcare and Alkem Laboratories--both makers of valsartan--for quality-control failures.

Charticle: How Jan Aushadhi stores are disrupting the Indian pharma market

Analysts point out that growth from product introductions has nearly halved over the last two years as the drug regulator has been more stringent about new combination drugs

Jan Aushadhi scheme may disrupt 20% of Indian pharma market sales: Report

India has over 5,000 Jan Aushadhi stores that cover a list of 800 plus drugs, both chronic and acute